Stay updated on Benralizumab in Anti-IL5 Inadequate Responders Clinical Trial
Sign up to get notified when there's something new on the Benralizumab in Anti-IL5 Inadequate Responders Clinical Trial page.

Latest updates to the Benralizumab in Anti-IL5 Inadequate Responders Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedAdded a minor site revision note: 'Revision: v3.3.2' replacing the previous 'Revision: v3.3.1' on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check18 days agoChange DetectedPage footer revision updated from v3.2.0 to v3.3.1. The study content and user-facing functionality remain unchanged.SummaryDifference0.1%

- Check26 days agoChange DetectedRemoved the government funding lapse notice about NIH operating status from the page; this is a non-critical notice and does not affect study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check40 days agoChange DetectedNo significant additions or deletions were detected; core study details, eligibility criteria, and locations appear unchanged.SummaryDifference0.5%

- Check68 days agoChange DetectedUpdate includes a critical operating status notice and a new software version (v3.2.0), indicating updated deployment with potential service impact; previous version reference (v3.1.0) was removed.SummaryDifference4%

- Check76 days agoChange DetectedPage updated to version v3.1.0 and removed multiple drug-safety related sections (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs) with no new substantive content added.SummaryDifference0.5%

Stay in the know with updates to Benralizumab in Anti-IL5 Inadequate Responders Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Benralizumab in Anti-IL5 Inadequate Responders Clinical Trial page.